Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16 studies found for:    pulmonary alveolar proteinosis
Show Display Options
Rank Status Study
1 Completed Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Condition: Hereditary Pulmonary Alveolar Proteinosis
Intervention: Drug: Leukine
2 Recruiting Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Condition: Autoimmune Pulmonary Alveolar Proteinosis
Intervention: Drug: GM-CSF
3 Unknown  Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
Conditions: Pulmonary Alveolar Proteinosis;   Primary Disease
Intervention: Drug: rituximab
4 Enrolling by invitation Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Condition: Pulmonary Alveolar Proteinosis
Interventions: Drug: GM-CSF [Leukine (Sargramostim)];   Procedure: WLL
5 Recruiting Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Condition: Autoimmune Pulmonary Alveolar Proteinosis
Interventions: Drug: molgramostim;   Drug: placebo
6 Terminated GM-CSF in Patients With Pulmonary Alveolar Proteinosis
Condition: Pulmonary Alveolar Proteinosis
Intervention: Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)
7 Recruiting A National Registry For Pulmonary Alveolar Proteinosis
Condition: Pulmonary Alveolar Proteinosis
Intervention:
8 Recruiting Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan
Condition: Pulmonary Alveolar Proteinosis, Autoimmune
Interventions: Drug: Sargramostim;   Drug: Placebo
9 Unknown  Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.
Condition: Pulmonary Alveolar Proteinosis
Interventions: Drug: rhGM-CSF;   Procedure: Whole Lung Lavage(WLL)
10 Recruiting Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT
Condition: Pulmonary Alveolar Proteinosis (PAP).
Intervention:
11 Active, not recruiting SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study
Condition: Pulmonary Alveolar Proteinosis, Autoimmune
Intervention: Drug: Sargramostim
12 Recruiting Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Conditions: Anticytokine Autoantibody-Associated Diseases;   Disseminated Non-Tuberculous Mycobacteria;   Chronic Mucocutaneous Candidiasis;   Pulmonary Alveolar Proteinosis (PAP)
Intervention: Drug: Rituximab/Rituxan
13 Completed Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects
Conditions: Pulmonary Alveolar Proteinosis;   Bronchiectasis;   Cystic Fibrosis;   Acute Respiratory Distress Syndrome
Interventions: Drug: Molgramostim;   Drug: Placebo
14 Recruiting European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Conditions: Lung Diseases, Interstitial;   Pulmonary Alveolar Proteinosis;   Pulmonary Eosinophilia;   Pulmonary Fibrosis;   Respiratory Distress Syndrome, Newborn;   Child
Intervention:
15 Recruiting Natural History Study of GATA2 Deficiency and Related Disorders
Conditions: Myelodysplasia;   Monocytopenia;   B Cell Lymphopenia;   NK Cell Deficiency;   Warts
Intervention:
16 Recruiting Epidemiology of Surfactant Protein-B Deficiency
Conditions: Lung Diseases;   Respiratory Distress Syndrome, Newborn;   Pulmonary Surfactants
Intervention:

Study has passed its completion date and status has not been verified in more than two years.